Melanoma

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed data from the RELATIVITY-047 trial of nivolumab plus relatlimab for patients with metastatic melanoma. This is the second of 2 articles based on this event.

In an interview with Targeted Oncology for Melanoma Monday, Meredith McKean, MD, MPH, discussed recent and upcoming advances in melanoma treatment.

The use of DecisionDx-Melanoma to guide better risk-aligned care for patients with cutaneous melanoma who are considered low-risk by staging is supported by study findings.

Primary end point data from the phase 2 KEYNOTE-695 study did not meet the prespecified end point of overall response rate for patients with advanced melanoma.

Promising results from a type C meeting with the FDA has led to a phase 2/3 trial of darovasertib and crizotinib being initiated in 2023 for patients with first-line HLA-A2 negative metastatic uveal melanoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed with other oncologists what efficacy and safety data aid them in choosing an immunotherapy regimen for patients with metastatic melanoma. This is the first of 2 articles based on this event.

Richard D. Carvajal, MD, discusses what he sees as the leading factors in making outcomes worse for patients with mucosal melanoma and how the disease differs from treatment for patients with cutaneous melanoma.

During a live webinar, Hussein Tawbi, MD, PhD, discussed first-line therapy for patients with stage IV melanoma, particularly the impact of targeting both PD-1 and LAG3 in these patients by using nivolumab and relatlimab.

Neither the LEAP-003 nor LEAP-017 studies study showed survival benefit with pembrolizumab plus lenvatinib for patients with melanoma or colorectal cancer.

Jason Luke, MD, discusses how the gated design of the REALITIVITY-047 led to results being delivered in phases for patients with advanced melanoma treated with the combination of relatlimab and nivolumab.

During a Targeted Oncology™ Case-Based Roundtable™ event, Anna C. Pavlick, DO, MSc, MBA, BSN, discussed first-line therapy for a patient with metastatic melanoma.

High-dose IL-2 is approved for use as a single agent in patients with metastatic melanoma. However, the agent induces limited efficacy and is known to have considerable toxicity.

Efficacy findings from CheckMate-76 have led the FDA to accept the supplemental biologics license application and the EMA to validate the type II variation marketing authorization application for nivolumab alone in stage IIB or IIC melanoma.

Jason Luke, MD, discussed the role played by the combination of nivolumab plus relatlimab in patients with advanced melanoma.

The FDA has granted a breakthrough therapy designation to mRNA-4157/V940 based on data from KEYNOTE-942 which showed that the addition of an mRNA vaccine to adjuvant pembrolizumab improved recurrence-free survival following resection of high-risk melanoma.

Dermalyser shows the potential to decrease the workload for dermatologists and replace it with an artificial intelligence tool to identify malignant melanomas among cutaneous lesions.

LNS8801 has proven to be safe, well-tolerated, and demonstrated clinical benefit in patients with advanced cancers. Now, the FDA has granted the agent orphan drug designation for metastatic cutaneous melanoma.

Findings from a phase 1/2 trial showed that sotigalimab plus pembrolizumab led to antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma.

Marc S. Ernstoff, MD, discusses metastatic melanoma and how patients may be managed.

In an interview with Targeted Oncology, Marc S. Ernstoff, MD, discusses recent updates in the management of metastatic melanoma.

A phase 2b trial of pembrolizumab plus a personalized mRNA vaccine resulted in improved recurrence-free survival in patients with resected high-risk melanoma, the first successful randomized trial of its kind.

Closing out his discussion on the management of metastatic melanoma, expert oncologist Sajeve Thomas, MD, summarizes unmet needs and looks toward future evolutions in the treatment paradigm.

Comprehensive insight from an expert oncologist regarding the adverse event profile of immunotherapy (IO) agents and how these can be mitigated while treating patients with metastatic melanoma.

Following his review of first-line treatment options in the setting of metastatic melanoma, Sajeve Thomas, MD, considers how he would manage patients at disease progression.

Expert perspective on the optimal selection and use of first-line therapy in patients diagnosed with metastatic melanoma in the context of the current treatment paradigm.

Sajeve Thomas, MD, reflects on the RELATIVITY-047 trial combining relatlimab, a LAG-3 inhibitor, with nivolumab, a PD-1 inhibitor, in the first-line setting of unresectable or metastatic melanoma.

A comprehensive review of how the first-line treatment armamentarium in unresectable or metastatic melanoma has evolved over time.

Expert oncologist Sajeve Thomas, MD, reviews the diagnosis and first-line management of a patient who presents with metastatic melanoma.

Additional data is needed for lifileucel before it is granted a biologics license application by the FDA for patients with unresectable or metastatic melanoma.

Ryan Sullivan, MD, explains how tumor infiltrating lymphocytes could impact the melanoma treatment landscape if approved by the FDA.